When biotechnology company Biogen announced the cancellation of the trial for their Alzheimer’s drug aducanumab, nearly 3,500 trial participants were left in limbo. Now,…
SAN DIEGO — I’m not a doctor. I’m not a scientist. I barely made it through my math and science classes in college. Actually,…
SAN DIEGO — The scientific data was virtually unreadable, the explanations often too complex for the layman or woman to understand. But there was…
SAN DIEGO — Headlining a top Alzheimer’s conference this week, the pharmaceutical company Biogen will for the first time share the data that led…
Scientists and analysts greeted yesterday’s announcement that Biogen is trying to resurrect aducanumab, its experimental Alzheimer’s drug, with caution and outright skepticism. Minutes after…
I wasn’t yet fully awake this morning when I started poking through my Facebook feed and saw the head-spinning news that Biogen had reversed…
In a dizzying reversal, Biogen announced today that it would seek approval from the U.S. Food and Drug Administration (FDA) to begin marketing its…
Sign up for a weekly digest of the latest research on Alzheimer’s and brain health.
Follow us